Terrault N, et al. - In patients with thrombocytopenia and chronic liver disease (CLD) undergoing scheduled procedures, the researchers performed 2 randomized, placebo-controlled, phase 3 trials to assess the safety and efficacy of avatrombopag in increasing platelet counts in this patient population. From February 2014 through January 2017, ADAPT-1 was conducted at 75 study sites in 20 countries. From December 2013 through January 2017, ADAPT-2 was conducted at 74 sites in 16 countries. They discovered that avatrombopag was superior to placebo in lessening the need for platelet transfusions or rescue procedures for bleeding in patients with thrombocytopenia and CLD undergoing a scheduled procedure in 2 phase 3 randomized trials.